In a phase 1 randomised placebo-controlled trial in 56 healthy adults, EDI048, a Cryptosporidium PI(4)K inhibitor, was well tolerated up to 400 mg twice daily for 5.5 days, with few mostly mild adverse events and minimal systemic exposure.
RCTn = 56
Jain et al. A First-in-Human Phase 1 Clinical Study in Healthy Volunteers to Assess the Safety, Tolerability, and Pharmacokinetics of EDI048, a Novel Promising Agent to Treat Enteric Cryptosporidiosis